Despite improved cost efficiency and reduced losses, the significant revenue decline is concerning. Traders should monitor whether the cost-cutting strategy can offset continued revenue pressure and whether the company can stabilize sales in international markets.
AMRN drugs
AMRN drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Feb 25 $14.05entry
- T+1 · 9mo ago +0.50%α +1.04% · $14.12
- T+5 · 9mo ago +3.49%α +4.59% · $14.54
- T+20 · 8mo ago +4.48%α +9.72% · $14.68
- T+60 · 6mo ago +1.57%α −5.38% · $14.27
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Amarin reported Q4 2025 financial results showing a 21% year-over-year decline in total net revenue to $49.2 million, driven by lower sales in Rest-of-World and Europe. However, the company significantly reduced operating expenses by 31%, narrowing its operating loss by 88% to $6.3 million. Net loss improved to $1.2 million from $48.6 million a year ago, and cash increased to $302.6 million. The improvements were attributed to cost-saving initiatives and restructuring efforts.
Key Financial Metrics
Key Facts
- Total net revenue decreased 21% YoY to $49.2 million in Q4 2025
- Operating expenses decreased 31% YoY to $29.5 million
- Operating loss narrowed 88% YoY to $6.3 million
- Net loss improved to $1.2 million from $48.6 million in Q4 2024
- Cash position increased to $302.6 million as of December 31, 2025
- Revenue decline attributed to Rest-of-World sales decrease and European transition impacts
Financial Impact
Revenue decreased by $13.1 million (21%) year-over-year, while operating expenses decreased by $13.5 million (31%)
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| U.S. | $41.1M | -7.0% |
| Europe | $2.3M | -42.0% |
| Rest-of-World | $3.1M | -74.0% |
Risk Factors
- Continued revenue decline, particularly in international markets
- Dependence on cost-cutting to improve financial performance
- Transition challenges in European sales model
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-068511 |
| Document: amrn-20260225.htm | 0001193125-26-068511 |
| Document: 0001193125-26-068511-index-headers.html | 0001193125-26-068511 |
| Document: 0001193125-26-068511-index.html | 0001193125-26-068511 |
| Document: 0001193125-26-068511.txt | 0001193125-26-068511 |
| CONTEXT: Previous Earnings (2026-02-25) | 0001193125-26-068511 |
Track record
8 reports on AMRN
The track record builds as more bullish or bearish reports settle.
Filters
- Oct 28, 202619d ago 8-K Neutral 5/10 No price data
- Oct 28, 202619d ago Press Release Neutral 5/10 Entry $12.75 Now $11.31 −11.26% settles Jan 26
- Oct 25, 202622d ago Press Release Mixed 6/10 Entry $12.09 Now $11.31 −6.45% settles Jan 22
- Aug 28, 202611w ago Press Release Neutral 4/10 Entry $13.97 Now $11.31 −19.04% settles Nov 23
- Jun 4, 202623w ago Court Ruling Bearish 7/10 Entry $13.80 to $13.97 Now $11.31 +18.04% ▼ −1.23% +0.65% vs SPY
- Apr 29, 202628w ago 8-K Neutral 4/10 Entry $14.29 to $13.55 Now $11.31 −20.85% ▼ −5.18% −9.29% vs SPY
- Mar 16, 202635w ago Press Release Neutral 4/10 Entry $15.42 to $14.20 Now $11.31 −26.65% ▼ −7.91% −18.40% vs SPY
- Feb 25, 202637w ago 8-K Bearish 6/10 Viewing Entry $14.05 to $14.27 Now $11.31 +19.50% ▼ −1.57% +5.38% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers